After years of decreasing rates, the prevalence of cocaine use has been increasing since 2012; cocaine is currently the second leading cause of overdose death (with opioids the first) associated with illicit drug use in the US
1,2 and the United Kingdom.
3 Cocaine use has taken a particular toll on certain vulnerable populations; for example, it is the leading cause of overdose death among Black persons.
4 However, treatments for cocaine use disorders are limited and, despite the performance of many clinical trials over several decades, no pharmacotherapy has been approved by government agencies in the US or Europe. The lack of approved treatments for cocaine use disorder is in contrast to the approval of naltrexone, methadone, and buprenorphine medications for the treatment of opioid use disorder
5-8; naltrexone, acamprosate, and disulfiram medications for the treatment of alcohol use disorder
9,10; and varenicline, bupropion, and nicotine replacement medications for the treatment of tobacco use disorder.
11,12